Benefits of Magnesium Sulfate in Organophosphate Toxicity

Benefits of Magnesium Sulfate in Organophosphate Toxicity - Benefits of Magnesium Sulfate in Organophosphate Toxicity

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025240

Enrollment

400

Registered

2017-12-31

Start date

2016-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organophosphate toxicity

Interventions

Treatment with 4g of magnesium sulfate IV + up to 10 g IM in addition to standard therapy with atropine. Standard therapy with atropine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients presenting to the Poison Control Centre diagnosed with moderate to severe organophosphate toxicity.

Exclusion criteria

Exclusion criteria: Heart block on ECG; History of Myocardial Infarction; History of hypersensitivity to magnesium sulfate; Hypercalcemia and/or hypermagnesemia.

Design outcomes

Primary

Measure	Time frame
Rates of morbidity and mortality in the hospital, and up to ten days post-discharge.	—

Secondary

Measure	Time frame
Side effects/toxicities attributable to magnesium sulfate treatment; Length of hospital stay; Duration of signs and symptoms of toxicity; Doses of other drugs used.	—

Countries

Asia(except Japan)

Contacts

Public ContactOmar Abbas Ahmed Malik

Dow University of Health Sciences Dow Medical College

omar.a.a.malik@gmail.com00923362363569

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026